Healthcare · NSE: CIPLA · BSE: 500087
Cipla: how the business works
Cipla makes medicines, including inhalers for breathing conditions, and sells them in India, the US, Africa and other markets, earning ₹28,163 crore of revenue in FY26.
Follow Cipla
Email me when Cipla's page is updated after results.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
Cipla Limited · Mumbai, Maharashtra · Founded 1935
Updated for Q2 FY27 · checked
- Revenue, FY26
- ₹28,163 cr
- Profit to shareholders, FY26
- ₹3,879 cr
- Manufacturing sites, FY26
- 48
- Incorporated
- 1935
- Promoter holding, 30 Sep 2026
- 29.21%
The short version
Cipla in 5 points
1 · What it sells
Cipla makes branded and generic medicines, including inhalers for breathing conditions, and its FY26 revenue from operations was ₹28,163 crore.
2 · Who pays it
In FY26, customers in India paid 45.0% of Cipla's revenue, the US 24.4%, Africa 15.2% and the rest of the world 15.4%.
3 · What it keeps from ₹100
Of every ₹100 that came in during FY26, Cipla kept ₹13.4 as profit, after a ₹276 crore one-off labour-code charge and including ₹882 crore of other income, while its EBITDA before the one-off charge was 20.9% of revenue (Cityfort calculation).
4 · Where the operating profit comes from
Cipla has reported a single segment since FY26, so it does not disclose which business earns its FY26 EBITDA of ₹5,883 crore before the one-off charge (Cityfort calculation); India gave 45.0% of revenue.
5 · The one thing to watch
North America sales fell from US$233 million in Q2 FY26 to US$172 million in Q2 FY27, and management said on 27 Oct 2026 it keeps its aim of a US$1 billion run rate towards the end of FY27.
Sources: From Cipla's FY26 annual report, its Q2 FY27 results, release and earnings call, and its Q4 FY26 earnings call · checked
Sources (6)
01Where the money goes · FY26
Where does ₹100 of Cipla's money go?
Cipla · FY26
Receipt for every ₹100
| Materials and goods bought | ₹32.9 |
|---|---|
| Employee costs | ₹18.5 |
| Other running costs | ₹25.4 |
| Depreciation and interest | ₹4.4 |
| One-off labour-code charge | ₹0.9 |
| Income tax | ₹4.7 |
| Kept as profit for shareholders | ₹13.4 |
| Total | ₹100 |
Each line = amount ÷ total money in × 100. Lines may not add to exactly ₹100 because of rounding.
How this is worked out
Cityfort calculation from the FY26 annual report: each line ÷ total money in (revenue of ₹28,163 crore plus ₹882 crore of other income) × 100. Profit is the shareholders' share: ₹9 crore more than money in minus the costs shown, because minority partners took ₹17 crore of losses and part-owned companies lost ₹8 crore.
Save this receipt as an image
Embed this receipt or the key numbers
Paste this code into a blog or website to show the card you choose, with a link back to this page.
Each week: the next company due to report results, explained in 5 points.
We'll email you once a week with what changed on Cityfort. Facts only, no tips. Unsubscribe any time.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
02The business in one line
What does Cipla do?
Buyers in India, the US, Africa and other markets pay Cipla for its medicines; materials, staff and running costs take most of the money, and ₹13.4 of every ₹100 that came in was left as profit in FY26.
- In FY26 customers in India gave 45.0% of Cipla's revenue, the US 24.4%, Africa 15.2% and the rest of the world 15.4%.
- Of every ₹100 that came in during FY26, ₹32.9 went on materials, ₹25.4 on other running costs and ₹18.5 on staff.
03Who pays it
Who pays Cipla?
Customers in India
45%
of revenue
Distributors and retailers that sell Cipla's prescription brands, trade generics and consumer products to patients. Share is of FY26 revenue by customer location.
Customers in the US
24.4%
of revenue
Buyers of Cipla's generic medicines in the US: ₹6,872 crore of revenue in FY26, down from ₹7,899 crore in FY25.
Customers in Africa
15.2%
of revenue
Private-market buyers in South Africa and other African countries, and governments and global health programmes buying through tenders.
Customers in the rest of the world
15.4%
of revenue
Buyers in other emerging markets and Europe, and companies buying drug ingredients.
- Customers in India45%
- Customers in the US24.4%
- Customers in Africa15.2%
- Customers in the rest of the world15.4%
How spread out the customers are
No single customer gave Cipla 10% or more of its revenue in FY26 or FY25, according to its segment note. Cipla's BRSR lists its customer types as business and institutional partners, channel partners, government agencies and individual consumers.
04How it makes money
How does Cipla make money?
A handful of US medicines can move Cipla's profit; when one stops, profit falls faster than sales.
In FY26 Cipla's revenue rose 2.2% but profit for shareholders fell 26.4%. North America sales fell 13% after generic Revlimid billing ended and lanreotide supply was paused. Staff and running costs kept rising, so EBITDA fell from 25.9% to 19.9% of revenue (20.9% before a one-off charge; Cityfort calculation).
EBITDA margin (Cityfort calculation)
25.9%19.9%
FY25 to FY26
- In India, doctors prescribe Cipla's brands and about 1.5 lakh retailers stock its trade generics.
- In the US, Cipla sells generics such as inhalers; its albuterol had 22% of the US albuterol inhaler market in Sep 2026.
- Single products matter: generic Revlimid billing ended in the Dec 2025 quarter, and lanreotide supply was paused in Jan 2026.
- When such a product stops, North America sales fall: down 13% in FY26 to ₹6,871 crore.
- Costs keep rising: employee costs grew from ₹4,833 crore in FY25 to ₹5,366 crore in FY26.
- Management said in May 2026 that FY27 margins would be higher in the second half, with the benefit of new US launches.
↺ Step 6 feeds back into step 1.
05Business segments · FY26
Which businesses make up Cipla?
One India
45%Prescription brands, trade generics and consumer health in India. Company grouping from its results release; Cipla has reported one audited segment since FY26.
Revenue ₹12,680 cr
North America
24.4%Generic medicines, many of them inhalers, mainly in the US.
Revenue ₹6,871 cr
One Africa
15.2%South Africa (₹3,364 crore), North and Sub-Saharan Africa, and tender sales through Cipla Global Access. The FY24 figures exclude Quality Chemicals (Uganda), sold in Q3 FY24: the FY24 total is ₹25,455 crore against reported revenue of ₹25,774 crore.
Revenue ₹4,287 cr
Emerging markets and Europe
12.7%Medicines sold in other emerging markets and Europe.
Revenue ₹3,576 cr
API and others
2.7%Drug ingredients sold to other companies, and other items.
Revenue ₹749 cr
How the mix changed
- One India
- North America
- One Africa
- Emerging markets and Europe
- API and others
Revenue by segment, FY24 to FY26.
₹ crore
See the numbers
06The numbers · Consolidated · ₹ crore
How has Cipla done?
Revenue
₹28,163 crFY26
Revenue rose every year, from ₹21,763 crore in FY22 to ₹28,163 crore in FY26, but Q2 FY27 revenue of ₹7,404 crore was 2.4% below Q2 FY26.
₹ crore
See the numbers
Net profit
₹3,879 crFY26
Profit for shareholders fell 26.4% to ₹3,879 crore in FY26, after a ₹276 crore one-off labour-code charge in Q3 FY26, and Q2 FY27 profit of ₹878 crore was 35.1% below Q2 FY26.
₹ crore
See the numbers
Net profit for every ₹100 of revenue
₹13.8FY26
Net profit per ₹100 of revenue fell from ₹19.1 in FY25 to ₹13.8 in FY26; EBITDA was 19.9% (₹5,607 crore) in FY26 after the ₹276 crore labour-code charge and 20.9% (₹5,883 crore) before it (Cityfort calculation), while Cipla reported 21.0%, which also leaves out a ₹42 crore associate impairment.
Net margin: ₹ of net profit per ₹100 of revenue
See the numbers
Free cash flow
₹861 crFY26
Free cash flow fell from ₹3,457 crore in FY25 to ₹861 crore in FY26, mainly because spending on intangible assets included ₹1,107 crore for perpetual rights to Novartis's Galvus brands.
₹ crore · cash from operations minus spending on plants and equipment
See the numbers
See all yearly numbers
EBITDA = profit before interest, tax and wear-and-tear of assets. Financial year runs April to March (March year end). Net profit is the share belonging to the company's owners.
Sources (19)
- Q4 FY22 / FY22 consolidated results XBRL
- Annual Report 2021-22 (FY22; NSE zip)
- Annual Report 2022-23 (FY23; NSE zip)
- Q4 FY23 / FY23 consolidated results XBRL
- Q4 FY24 / FY24 consolidated results XBRL
- Annual Report 2023-24 (FY24)
- Q4 FY25 / FY25 consolidated results, Integrated Filing (Financials) XBRL
- Integrated Annual Report 2024-25 (FY25)
- Q4 FY26 / FY26 consolidated results, Integrated Filing (Financials) XBRL
- Integrated Annual Report 2025-26 (FY26)
- Press release: Q4 FY26 and FY26 results
- Q3 FY25 consolidated results XBRL
- Q1 FY26 consolidated results, Integrated Filing (Financials) XBRL
- Q2 FY26 consolidated results, Integrated Filing (Financials) XBRL
- Q3 FY26 consolidated results, Integrated Filing (Financials) XBRL
- Unaudited financial results Q3 FY26 (quarter ended 31 Dec 2025; scanned)
- Q1 FY27 consolidated results, Integrated Filing (Financials) XBRL
- Q2 FY27 consolidated results, Integrated Filing (Financials) XBRL
- Press release: Q2 FY27 financial results
07Who runs it
Who runs Cipla, and did they deliver?
Dr Y K Hamied
Chairman
Member of the promoter family.
Achin Gupta
Managing Director and Global CEO · since 2026
From 1 Apr 2026 for five years, to 31 Mar 2031; earlier Global Chief Operating Officer. He took over from Umang Vohra, who completed his term on 31 Mar 2026.
Ashish Adukia
Global Chief Financial Officer
P R Ramesh
Vice-Chairman and Lead Independent Director · since 2026
Vice-Chairman from 1 Apr 2026.
Rajendra Chopra
Company Secretary
What they said, and what happened
3 missed · 1 delivered · 3 too early to tell
Said on 13 May 2025
Management said its FY26 EBITDA margin outlook was "in the range of about 23.5% to 24.5%".
MissedWhat happened
On 23 Jan 2026 management said the FY26 EBITDA margin would be around 21%. Cipla reported 21.0% for FY26.
Said on 23 Jan 2026
Management said: "We currently expect Lanreotide resupply to resume in H1 FY'27."
MissedWhat happened
On 27 Oct 2026, after H1 FY27, Achin Gupta said Cipla was pursuing two parallel paths to resume supply: Pharmathen's remediation and a new site.
Said on 23 Apr 2026
Cipla said generic Ventolin was "expected to be launched in H1 of FY 2026-27" in the US.
DeliveredWhat happened
Management said on 23 Jul 2026 that generic Ventolin was launched in Q1 FY27.
Said on 27 Jul 2026
Cipla said generic Advair Diskus was "expected to be launched in Q2 of FY 2026-27" in the US.
MissedWhat happened
Cipla announced the US FDA approval and the expected Q2 launch in the same 27 Jul 2026 filing; the launch did not happen in Q2. On 27 Oct 2026 Achin Gupta said it "is getting launched in Q3".
Said on 13 May 2026
Management said its aim was for North America to cross a US$1 billion run rate towards the end of FY27.
Too early to tellWhat happened
North America sales were US$172 million in Q2 FY27. On 27 Oct 2026 management said it was keeping this aim.
Said on 13 May 2026
Management said it expects FY27 EBITDA margins "in the range of 18.5% to 20%", improving quarter on quarter, mostly in the second half.
Too early to tellWhat happened
Cipla reported an 18.7% EBITDA margin in Q2 FY27, after 16.7% in Q1 FY27 (Cityfort calculation from the Q1 FY27 results). Management kept the range on 27 Oct 2026.
Said on 27 Oct 2026
Management said that in FY27 research spending would stay within 6% to 7% of revenue.
Too early to tellWhat happened
Research spending was ₹423 crore in Q2 FY27, 5.7% of sales.
Sources (14)
- Integrated Annual Report 2025-26 (FY26)
- Shareholding pattern as of 30 Sep 2026 (NSE XBRL)
- Umang Vohra resigns as director w.e.f. 1 Apr 2026 on completing his term as MD & Global CEO
- Board: up to US$100 mn into Cipla (EU) for InvaGen; P R Ramesh Vice-Chairman
- Q4 FY25 earnings call transcript (call 13 May 2025)
- Q3 FY26 earnings call transcript (call 23 Jan 2026)
- Press release: Q4 FY26 and FY26 results
- Q2 FY27 earnings call transcript (call 27 Oct 2026)
- USFDA approval for first AB-rated generic of Ventolin HFA (albuterol)
- Q1 FY27 earnings call transcript (call 23 Jul 2026)
- USFDA approval for generic Advair Diskus
- Q4 FY26 earnings call transcript (call 13 May 2026)
- Press release: Q2 FY27 financial results
- Q1 FY27 consolidated results, Integrated Filing (Financials) XBRL
08What could go wrong
What could go wrong for Cipla?
- Regulation
US FDA status of Cipla's plants
The Pithampur plant has been classed OAI by the US FDA since Aug 2023 and had a warning letter in Nov 2023. A follow-up inspection in Aug 2026 ended with 7 observations. Cipla said OAI status may delay or withhold pending US product approvals.
Watch The US FDA's classification of the Aug 2026 Pithampur inspection.
- Concentration
A few US products and partners
North America sales fell 13% in FY26 after generic Revlimid billing ended and supply of lanreotide, made by partner Pharmathen, was paused and later recalled. Achin Gupta said on 27 Oct 2026 that the US$1 billion run-rate aim does not include lanreotide.
Watch North America sales in US dollars each quarter (US$172 million in Q2 FY27).
- Pricing
Price controls and competition
Cipla's FY26 annual report says "Government price controls, competitor and customer pressures collectively erode profitability", and names more competition in chronic medicines, particularly cardiometabolic (heart and blood-sugar) and anti-obesity medicines.
Watch One India growth each quarter (+12% in Q2 FY27) and gross margin.
- Legal
NPPA overcharging claims
The NPPA alleges Cipla overcharged for price-controlled drugs; notices under litigation total ₹2,011 crore, including ₹1,148 crore of interest. Cipla has made no provision. CARE lists this liability crystallising as a factor that could lead to a lower rating.
Watch Supreme Court hearings on Cipla's appeal, and any provision in the results.
- Execution
Margins below earlier targets
Cipla's FY26 EBITDA margin was 21.0%, against the 23.5–24.5% range management gave in May 2025. For FY27 management gave 18.5–20%; Cipla reported 18.7% in Q2 FY27.
Watch Quarterly EBITDA margin in Q3 and Q4 FY27.
- Execution
Delays in US launches
Cipla said on 27 Jul 2026 it expected to launch generic Advair in Q2 FY27; on 27 Oct 2026 Achin Gupta said it "is getting launched in Q3". Cipla said on 14 Jan 2026 it expected lanreotide resupply in H1 FY27; it had not resumed by 27 Oct 2026.
Watch Generic Advair sales and any lanreotide restart in Cipla's results releases.
Sources (15)
- USFDA classifies Pithampur inspection as Official Action Indicated (OAI)
- USFDA Warning Letter dated 17 Nov 2023 for Pithampur
- USFDA follow-up cGMP inspection at Pithampur, 17-25 Aug 2026: 7 observations in Form 483
- Press release: Q4 FY26 and FY26 results
- Q3 FY26 earnings call transcript (call 23 Jan 2026)
- Update on lanreotide supply after USFDA observations at Pharmathen
- Cipla USA to recall unexpired lanreotide batches
- Press release: Q2 FY27 financial results
- Q2 FY27 earnings call transcript (call 27 Oct 2026)
- Integrated Annual Report 2025-26 (FY26)
- Unaudited financial results Q2 FY27 (quarter and half year ended 30 Sep 2026)
- CARE Ratings press release: Cipla Limited, bank facilities reaffirmed CARE AAA; Stable / CARE A1+
- Q4 FY25 earnings call transcript (call 13 May 2025)
- Q4 FY26 earnings call transcript (call 13 May 2026)
- USFDA approval for generic Advair Diskus
09Supporters and critics
What do supporters and critics point to?
What supporters point to
- Revenue rose every year from FY22 to FY26, from ₹21,763 crore to ₹28,163 crore.
- One India sales rose 12% in Q2 FY27 to ₹3,516 crore, which Cipla called its highest quarterly sales.
- The US FDA approved generic Ventolin and generic Advair in 2026, and Cipla's albuterol had 22% of the US albuterol inhaler market in Sep 2026.
- On 30 Sep 2026 cash and liquid investments of ₹8,238 crore exceeded borrowings of ₹267 crore; CARE rates Cipla AAA (Stable).
- No promoter shares were pledged in any of the 12 quarters from Dec 2023 to Sep 2026.
What critics point to
- FY26 profit for shareholders fell 26.4% to ₹3,879 crore while revenue rose 2.2%, and Q2 FY27 profit was 35.1% lower than a year earlier.
- North America sales fell from US$233 million in Q2 FY26 to US$172 million in Q2 FY27.
- The Pithampur plant has been classed OAI by the US FDA since Aug 2023; its Aug 2026 inspection ended with 7 observations.
- Cipla said in Jan 2026 it expected lanreotide supply to resume in H1 FY27; it had not restarted by 27 Oct 2026.
- The NPPA alleges overcharging; ₹2,011 crore of notices are under litigation and Cipla has made no provision.
10What to watch next
What should you watch next at Cipla?
Next event
Q3 FY27 results
Date not announced yet.
Pithampur inspection outcome
The US FDA's classification of the Aug 2026 follow-up inspection, which ended with 7 observations; the plant has been OAI since Aug 2023.
US sales and launches
North America sales were US$172 million in Q2 FY27. On 27 Oct 2026 Achin Gupta said generic Advair would launch in Q3, and management kept its US$1 billion run-rate aim for the end of FY27.
Margins
Cipla reported an 18.7% EBITDA margin in Q2 FY27; management's FY27 range, given on 13 May 2026, is 18.5–20%.
11Key facts
Key facts about Cipla
- What does Cipla do?
- Cipla Ltd is a Mumbai-based drug maker, incorporated in 1935, that makes and sells medicines in India, the US, Africa and other markets. Cipla's FY26 revenue from operations was ₹28,163 crore, and it reported 48 manufacturing sites in its FY26 annual report.
- How does Cipla make money?
- Cipla sells branded medicines that doctors prescribe in India, generic (off-patent) medicines in the US, Africa and other countries, and drug ingredients to other companies. In FY26 Cipla's India business sold ₹12,680 crore, North America ₹6,871 crore, Africa ₹4,287 crore and emerging markets and Europe ₹3,576 crore.
- Who are Cipla's customers?
- In FY26 Cipla's revenue came 45.0% from customers in India, 24.4% from the US, 15.2% from Africa and 15.4% from the rest of the world. No single customer gave Cipla 10% or more of its revenue in FY26 or FY25.
- How big is Cipla?
- Cipla's FY26 revenue from operations was ₹28,163 crore and its profit for shareholders was ₹3,879 crore. Cipla reported more than 31,000 permanent employees and workers across 18 countries in its FY26 annual report.
- Who owns Cipla?
- On 30 Sep 2026 Cipla's promoter group, the Hamied family with its trusts and companies, held 29.21% of the shares. Indian institutions held 34.94% (mutual funds 20.78%), foreign institutions 20.25% and other shareholders 15.60%. No promoter shares were pledged.
- Why did Cipla's profit fall in FY26?
- Cipla's FY26 profit for shareholders fell 26.4% to ₹3,879 crore while revenue rose 2.2%. Cipla's North America revenue fell 13% to ₹6,871 crore after billing of generic Revlimid (lenalidomide) ended and supply of lanreotide, made by a partner, was paused in Jan 2026.
- How did Cipla do in Q2 FY27?
- In Q2 FY27 (Jul–Sep 2026) Cipla's revenue fell 2.4% to ₹7,404 crore and its profit for shareholders fell 35.1% to ₹878 crore. Cipla's India sales rose 12% to ₹3,516 crore, while North America sales fell 19% to ₹1,643 crore.
- How much debt does Cipla have?
- On 30 Sep 2026 Cipla had borrowings of ₹267 crore and cash and liquid investments of ₹8,238 crore, plus ₹432 crore of lease liabilities. CARE Ratings rated Cipla's bank facilities CARE AAA (Stable) on 26 Aug 2025.
- What dividend does Cipla pay?
- Cipla's dividend for FY26 was ₹13 per share, 27.1% of its FY26 basic earnings per share of ₹48.03 (Cityfort calculation from the FY26 annual report). For FY25 Cipla paid ₹16, including a ₹3 special dividend for its 90th year.
- Who runs Cipla?
- Achin Gupta has been Cipla's Managing Director and Global CEO since 1 Apr 2026, after Umang Vohra completed his term. Dr Y K Hamied, of the promoter family, is Cipla's Chairman, and Ashish Adukia is its Global CFO.
Sources (13)
- Integrated Annual Report 2025-26 (FY26)
- Business Responsibility and Sustainability Report FY26
- Press release: Q4 FY26 and FY26 results
- Q4 FY26 / FY26 consolidated results, Integrated Filing (Financials) XBRL
- Shareholding pattern as of 30 Sep 2026 (NSE XBRL)
- Q3 FY26 earnings call transcript (call 23 Jan 2026)
- Update on lanreotide supply after USFDA observations at Pharmathen
- Q2 FY27 consolidated results, Integrated Filing (Financials) XBRL
- Press release: Q2 FY27 financial results
- Unaudited financial results Q2 FY27 (quarter and half year ended 30 Sep 2026)
- CARE Ratings press release: Cipla Limited, bank facilities reaffirmed CARE AAA; Stable / CARE A1+
- Integrated Annual Report 2024-25 (FY25)
- Umang Vohra resigns as director w.e.f. 1 Apr 2026 on completing his term as MD & Global CEO
Terms on this page
- Capital expenditure (capex)
- Credit rating
- Dividend payout ratio
- EBITDA
- FII and DII holding
- Free cash flow
- Market capitalisation
- Net debt
- Net profit
- Operating margin
Each explains the term in plain English, with the same number from other companies on Cityfort.
Go deeper
More detail from the same filings. Open any section.
12What it sells
12What it sells
What does Cipla sell?
Medicines in India (One India)
Prescription brands, lower-priced trade generics sold through about 1.5 lakh retailers, and consumer health products: ₹12,680 crore of sales in FY26, up 9%. CARE's Aug 2025 report put Cipla's share of India's respiratory medicine market at 25.3%.
Generic medicines in North America
Off-patent medicines, many of them inhalers, sold mainly in the US: ₹6,871 crore (US$780 million) in FY26, down 13%. Cipla's generic albuterol inhaler had 22% of the US albuterol inhaler market (IQVIA, week to 25 Sep 2026).
Medicines in Africa (One Africa)
Branded and generic medicines in South Africa and other African countries, plus medicines sold to institutions through tenders (Cipla Global Access): ₹4,287 crore in FY26, of which South Africa ₹3,364 crore.
Emerging markets and Europe
Medicines sold in other emerging markets and in Europe: ₹3,576 crore in FY26, up 8%.
Drug ingredients (API) and others
Active pharmaceutical ingredients, the substance in a medicine that does the work, sold to other companies, and other small items: ₹749 crore in FY26.
What it does
- Does: Makes medicines at 48 manufacturing sites (FY26 annual report)
- Does: Sells inhalers and other generics in the US, including generic Ventolin, launched in Q1 FY27
- Does: Sells medicines to governments and institutions through tenders, mainly in Africa
- Does: Sells Eli Lilly's tirzepatide in India as Yurpeak, for obesity and type 2 diabetes, under a distribution agreement launched on 10 Dec 2025
What it does not do
- Does not: Does not report profit by business or region: since FY26 it reports a single segment, 'Pharmaceutical and related products'
- Does not: Does not make lanreotide itself: a partner, Pharmathen in Greece, made it for Cipla's US business
- Does not: Does not own Yurpeak: Eli Lilly owns the medicine, and Cipla markets and distributes it in India
13How the money flows
13How the money flows · FY26
How does money flow through Cipla?
Money in
- Revenue from operations₹28,163 cr
- Other income₹882 cr
The company
Cipla
₹29,045 cr came in
Money out
- Materials and goods bought₹9,549 cr
- Employee costs₹5,366 cr
- Other running costs₹7,364 cr
- Depreciation and interest₹1,265 cr
- One-off charge (higher gratuity and leave costs under new labour codes)₹276 cr
- Income tax₹1,354 cr
- Net profit for Cipla shareholders₹3,879 cr
- In FY26 Cipla's medicines brought in ₹28,163 crore of revenue, plus ₹882 crore of other income.
- Materials and goods bought took ₹9,549 crore and employees ₹5,366 crore.
- Other running costs took ₹7,364 crore, and depreciation and interest ₹1,265 crore.
- A one-off labour-code charge took ₹276 crore and income tax ₹1,354 crore.
- What was left for Cipla's shareholders was ₹3,879 crore of profit.
14What it needs to run
14What it needs to run
What does Cipla need to run?
Plants
48 manufacturing sites in the FY26 annual report. The Indian parent company's FY26 BRSR lists 39 plants in India and 9 abroad.
US FDA inspections
Plants that make medicines for the US are inspected by the US FDA. From Jun 2024 to Jun 2026 inspections at Patalganga, Kurkumbh, Goa, Virgonagar, Bommasandra and Verna were classed VAI (voluntary action indicated), while Pithampur has been OAI since Aug 2023.
Research
₹1,974 crore spent on research and development in FY26; ₹423 crore in Q2 FY27, 5.7% of sales.
Partners and licences
Some medicines come from other companies: lanreotide from Pharmathen, Yurpeak from Eli Lilly, four Pfizer brands in India under a five-year deal, and Galvus brands bought from Novartis.
People
More than 31,000 permanent employees and workers across 18 countries (FY26 annual report).
Sources (14)
- Integrated Annual Report 2025-26 (FY26)
- Business Responsibility and Sustainability Report FY26
- USFDA classifies Patalganga inspection as VAI
- USFDA classifies Kurkumbh inspection as VAI
- USFDA classifies Goa inspection (Jun 2024) as VAI
- USFDA classifies Virgonagar inspection as VAI
- USFDA classifies Bommasandra inspection as VAI
- USFDA classifies Verna (Goa) Apr 2026 inspection as VAI
- USFDA classifies Pithampur inspection as Official Action Indicated (OAI)
- Press release: Q2 FY27 financial results
- Update on lanreotide supply after USFDA observations at Pharmathen
- Launch of Yurpeak (tirzepatide) in India under distribution agreement with Eli Lilly
- Exclusive 5-year supply and marketing agreement for four Pfizer brands in India
- Unaudited financial results Q3 FY26 (quarter ended 31 Dec 2025; scanned)
15Where it sells
15Where it sells · FY26
Where does Cipla sell?
- India45%
- United States24.4%
- Africa15.2%
- Rest of the world15.4%
Sources (1)
16Competitors and what protects it
16Competitors and what protects it
Who does Cipla compete with?
Sun Pharma
NSE: SUNPHARMA
Sells medicines in India: ₹21,538 crore of India sales and an 8.5% share in the 12 months to Jun 2026, per AIOCD data in Sun Pharma's presentation.
Abbott (with Abbott Healthcare and Novo)
Counted together in the same AIOCD data: ₹14,851 crore of India sales and a 5.9% share in the 12 months to Jun 2026.
Mankind Pharma
Sells medicines in India: ₹13,922 crore of India sales and a 5.5% share in the 12 months to Jun 2026, per the same AIOCD data.
Torrent Pharmaceuticals
Sells medicines in India: ₹12,801 crore of India sales and a 5.0% share in the 12 months to Jun 2026, per the same AIOCD data.
What protects the business
Each strength is scored 1 (weak) to 5 (strong) for the business, with the reason. It is not a rating of the share.
- Respiratory medicines in India4 of 5
CARE's Aug 2025 report put Cipla's share of India's respiratory medicine market at 25.3%, with Cipla second in urology and chronic medicines.
- US inhalers3 of 5
Cipla's albuterol had 22% of the US albuterol inhaler market (IQVIA, week to 25 Sep 2026). Generic Ventolin launched in Q1 FY27 and generic Advair was approved on 27 Jul 2026.
- Size in India3 of 5
₹14,839 crore of India medicine sales and a 5.8% share in the 12 months to Jun 2026 (AIOCD), against 8.5% for Sun Pharma.
- Africa3 of 5
Cipla says it is second in South Africa's prescription market (IQVIA, Aug 2026). One Africa sold ₹4,287 crore in FY26, up 12%.
- Cash on hand5 of 5
On 30 Sep 2026 cash and liquid investments of ₹8,238 crore against borrowings of ₹267 crore. CARE rated Cipla AAA (Stable) on 26 Aug 2025.
Weak spot
A few US products and plants
North America sales fell 13% in FY26 after generic Revlimid billing ended and lanreotide, made by a partner, was paused. The Pithampur plant has been classed 'official action indicated' (OAI) by the US FDA since Aug 2023.
Sources (12)
- Sun Pharmaceutical Industries: investor presentation, September 2026 (India formulation market share chart, AIOCD AWACS MAT Jun 2026)
- CARE Ratings press release: Cipla Limited, bank facilities reaffirmed CARE AAA; Stable / CARE A1+
- Press release: Q2 FY27 financial results
- USFDA approval for first AB-rated generic of Ventolin HFA (albuterol)
- USFDA approval for generic Advair Diskus
- Q1 FY27 earnings call transcript (call 23 Jul 2026)
- Press release: Q4 FY26 and FY26 results
- Q2 FY27 consolidated results, Integrated Filing (Financials) XBRL
- Unaudited financial results Q2 FY27 (quarter and half year ended 30 Sep 2026)
- Q3 FY26 earnings call transcript (call 23 Jan 2026)
- Update on lanreotide supply after USFDA observations at Pharmathen
- USFDA classifies Pithampur inspection as Official Action Indicated (OAI)
17Where growth could come from
17Where growth could come from
Where could Cipla's growth come from?
Management said on the Q4 FY26 call (13 May 2026) that it expects FY27 EBITDA margins "in the range of 18.5% to 20%", improving each quarter, mostly in the second half. It also aims for North America to cross a US$1 billion run rate towards the end of FY27. On the Q2 FY27 call (27 Oct 2026) management said it was keeping both.
Medicines in India
Working₹3,516 crore, Q2 FY27 (+12%)
Cipla said One India had its "highest quarterly sales" in Q2 FY27. Additions include Yurpeak (Dec 2025), four Pfizer brands (Dec 2025) and perpetual rights to Novartis's Galvus brands.
Status: Working, on track against what the company said.
North America
BehindUS$172 million, Q2 FY27 (US$233 million a year earlier)
North America sales fell 19% in rupees to ₹1,643 crore in Q2 FY27, after generic Revlimid billing ended and lanreotide supply was paused.
Status: Behind, behind the company's own plan.
New US inhalers
EarlyGeneric Ventolin launched Q1 FY27; generic Advair approved 27 Jul 2026
Management said on 23 Jul 2026 that generic Ventolin has a six-month exclusivity period. Achin Gupta said on 27 Oct 2026 that generic Advair "is getting launched in Q3".
Status: Early, too early to judge.
Yurpeak (tirzepatide) in India
EarlyLaunched 10 Dec 2025
A weekly injection for obesity and type 2 diabetes, marketed under an agreement with Eli Lilly. Achin Gupta said on 27 Oct 2026 that adoption of tirzepatide showed month-on-month growth rates of 5% to 10%, and that Yurpeak had become the second-largest GLP-1 brand.
Status: Early, too early to judge.
Africa
Mixed₹1,171 crore, Q2 FY27 (−1%)
One Africa sales rose 12% in FY26 to ₹4,287 crore, then dipped 1% in Q2 FY27; South Africa fell 3% in the quarter.
Status: Mixed, partly on track.
Biosimilars and licensed medicines
New60:40 biologics joint venture with Kemwell (Mar 2026)
In Q2 FY27 Cipla licensed US rights to Qilu's biosimilar of pembrolizumab (Keytruda), a cancer drug, which Qilu develops and supplies. A biosimilar is a close copy of a biological medicine.
Status: New, recently announced.
Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.
Sources (15)
- Q4 FY26 earnings call transcript (call 13 May 2026)
- Q2 FY27 earnings call transcript (call 27 Oct 2026)
- Press release: Q2 FY27 financial results
- Launch of Yurpeak (tirzepatide) in India under distribution agreement with Eli Lilly
- Exclusive 5-year supply and marketing agreement for four Pfizer brands in India
- Unaudited financial results Q3 FY26 (quarter ended 31 Dec 2025; scanned)
- Press release: Q2 FY26 results
- Q3 FY26 earnings call transcript (call 23 Jan 2026)
- Update on lanreotide supply after USFDA observations at Pharmathen
- USFDA approval for first AB-rated generic of Ventolin HFA (albuterol)
- USFDA approval for generic Advair Diskus
- Q1 FY27 earnings call transcript (call 23 Jul 2026)
- Press release: Q4 FY26 and FY26 results
- 60:40 biologics joint venture agreement with Kemwell Biopharma
- Investor presentation Q2 FY27
18Financial strength and debt
18Financial strength · 30 Sep 2026
How much debt does Cipla have?
- Total debt₹267 cr
- Cash and investments₹8,238 cr
- Net cash (cash minus debt)₹7,971 cr
- Net worth (shareholders' money)₹35,396 cr
- Debt to equity
- 0.01×
- ₹ of debt for every ₹1 of shareholders' money
- Borrowings exclude lease liabilities (rent owed under leases) of ₹432 crore.
- Cash and liquid investments = cash, other bank balances and current investments. Net worth is the equity belonging to Cipla's shareholders.
- Cipla's own measure, on its own wider definition, was a net cash position of ₹9,823 crore on 30 Sep 2026.
- NPPA demand notices under litigation total ₹2,011 crore (principal ₹863 crore, interest ₹1,148 crore); Cipla has made no provision for them (see governance signals).
19Who owns it
19Who owns it · Q2 FY27
Who owns Cipla?
- Promoters (founders or parent company)29.2%
- Foreign institutions (FII)20.3%
- Indian institutions (DII)34.9%
- Public and others15.6%
Promoter pledge
No promoter shares were pledged in Q2 FY27.
How ownership changed
* Pledged = share of the promoters' own holding reported as pledged. In older filings this can include shares “otherwise encumbered”; the governance flags say when.
Sources (12)
- Shareholding pattern as of 31 Dec 2023 (NSE XBRL)
- Shareholding pattern as of 31 Mar 2024 (NSE XBRL)
- Shareholding pattern as of 30 Jun 2024 (NSE XBRL)
- Shareholding pattern as of 30 Sep 2024 (NSE XBRL)
- Shareholding pattern as of 31 Dec 2024 (NSE XBRL)
- Shareholding pattern as of 31 Mar 2025 (NSE XBRL)
- Shareholding pattern as of 30 Jun 2025 (re-filed 21 Oct 2025) (NSE XBRL)
- Shareholding pattern as of 30 Sep 2025 (NSE XBRL)
- Shareholding pattern as of 31 Dec 2025 (NSE XBRL)
- Shareholding pattern as of 31 Mar 2026 (revised filing 11 Aug 2026; original 21 Apr 2026) (NSE XBRL)
- Shareholding pattern as of 30 Jun 2026 (NSE XBRL)
- Shareholding pattern as of 30 Sep 2026 (NSE XBRL)
20What it does with profit
20What it does with profit
What does Cipla do with its profit?
Dividend per share
₹13.00FY26
Dividend paid for each share, by financial year.
₹ per share
See the numbers
No buybacks or fund raises in the period covered.
Sources (10)
- Annual Report 2021-22 (FY22; NSE zip)
- Q4 FY22 / FY22 consolidated results XBRL
- Annual Report 2022-23 (FY23; NSE zip)
- Q4 FY23 / FY23 consolidated results XBRL
- Annual Report 2023-24 (FY24)
- Q4 FY24 / FY24 consolidated results XBRL
- Integrated Annual Report 2024-25 (FY25)
- Q4 FY25 / FY25 consolidated results, Integrated Filing (Financials) XBRL
- Integrated Annual Report 2025-26 (FY26)
- Q4 FY26 / FY26 consolidated results, Integrated Filing (Financials) XBRL
21Governance signals
21Governance signals
What do Cipla's governance filings show?
- Auditor
- B S R & Co. LLP, since 2026
- Auditor changes
- 25 Jun 2026: Walker Chandiok & Co LLP → B S R & Co. LLP (Rotation: Walker Chandiok completed its second five-year term at the 90th AGM on 25 Jun 2026. Shareholders appointed B S R for five years, as the board recommended on 13 May 2025.)
- Audit qualifications
- None reported
- Related-party dealings
- Related-party transaction amounts were not extracted for this page. NPPA price demands jointly addressed to Cipla and Okasa, a promoter-group company, total ₹9.96 crore; Cipla says it is not the manufacturer and not liable.
- Credit rating
- CARE Ratings CARE AAA (long term), CARE A1+ (short term), bank facilities of ₹2,268 crore (outlook Stable), 26 Aug 2025
A credit rating describes the company's ability to repay debt. It is not a rating of the share.
Flags to know about
regulatory · 25 Aug 2026
US FDA status of the Pithampur plant
The US FDA classed Cipla's Pithampur (Indore) plant 'official action indicated' (OAI) in Aug 2023 and issued a warning letter dated 17 Nov 2023. A follow-up inspection on 17–25 Aug 2026 ended with 7 observations; Cipla had disclosed no outcome in the filings checked to 11 Nov 2026. Cipla said an OAI status may delay or withhold pending product approvals.
regulatory · 9 Mar 2026
FDA findings at a partner's plant; lanreotide recall
The US FDA inspected Pharmathen's plant in Rodopi, Greece, which makes lanreotide for Cipla USA, in Nov 2025, with 9 observations, and classed it OAI (Cipla disclosed this on 21 Feb 2026). Cipla USA then recalled unexpired lanreotide batches (filed 9 Mar 2026).
other · 27 Oct 2026
NPPA overcharging claims
Since 1998 the National Pharmaceutical Pricing Authority (NPPA), the drug-price regulator, has sent Cipla demand notices alleging overcharging under the 1995 drug price control order. Notices under litigation total ₹2,011 crore. Cipla deposited ₹175.08 crore under a 2003 Supreme Court order and ₹27.07 crore in Jul 2025. Its petition against a Feb 2024 Bombay High Court order is pending in the Supreme Court, and it has made no provision, citing legal advice.
other · 15 May 2024
Promoter holding fell
Promoter-group members sold 2.53% of Cipla's shares on 15 May 2024 "for the purpose of creating liquidity for specific needs including philanthropy". The promoter holding was 33.47% in Mar 2024, 30.92% in Sep 2024, 29.19% in Dec 2024 and 29.21% in Sep 2026.
other · 30 Mar 2026
New managing director
Umang Vohra stepped down as a director with effect from 1 Apr 2026 on completing his term as MD and Global CEO; Achin Gupta took over on 1 Apr 2026.
Sources (18)
- 90th AGM approves B S R & Co. LLP; Walker Chandiok & Co LLP completes second term
- Unaudited financial results Q2 FY27 (quarter and half year ended 30 Sep 2026)
- Board recommends B S R & Co. LLP as statutory auditor from the 90th AGM
- CARE Ratings press release: Cipla Limited, bank facilities reaffirmed CARE AAA; Stable / CARE A1+
- USFDA classifies Pithampur inspection as Official Action Indicated (OAI)
- USFDA Warning Letter dated 17 Nov 2023 for Pithampur
- USFDA follow-up cGMP inspection at Pithampur, 17-25 Aug 2026: 7 observations in Form 483
- Clarification: USFDA Form 483 at partner Pharmathen (lanreotide supplier)
- Update on lanreotide supply after USFDA observations at Pharmathen
- USFDA classifies Pharmathen (Rodopi, Greece) inspection as OAI
- Cipla USA to recall unexpired lanreotide batches
- Clarification: promoter group members sold 2.53% of shares on 15 May 2024
- Shareholding pattern as of 31 Mar 2024 (NSE XBRL)
- Shareholding pattern as of 30 Sep 2024 (NSE XBRL)
- Shareholding pattern as of 31 Dec 2024 (NSE XBRL)
- Shareholding pattern as of 30 Sep 2026 (NSE XBRL)
- Umang Vohra resigns as director w.e.f. 1 Apr 2026 on completing his term as MD & Global CEO
- Integrated Annual Report 2025-26 (FY26)
22What the market paid
22What the market paid · price as of 11 Nov 2026
What did the market pay for Cipla on 11 Nov 2026?
Price as of 11 Nov 2026 (shown for education; prices change daily).
Price as of 11 Nov 2026: ₹1,419.90, the NSE closing price. Market value = price × 807,870,615 shares (30 Sep 2026) = ₹114,710 crore (Cityfort calculation). P/E (price ÷ earnings per share) = price ÷ basic earnings per share of the last four quarters (Q3 FY26 to Q2 FY27, ₹35.87) = 39.6. P/B = market value ÷ shareholders' equity on 30 Sep 2026 (₹35,396 crore) = 3.2. Dividend yield = FY26 dividend of ₹13 ÷ price = 0.92%.
- Share price
- ₹1,419.90
- Market value (market cap)
- ₹114,710 cr
- P/E
- 39.6×
- P/B
- 3.2×
Source: NSE capital market bhavcopy, 11 Nov 2026 (CIPLA EQ close); Shareholding pattern as of 30 Sep 2026 (NSE XBRL); Q2 FY27 consolidated results, Integrated Filing (Financials) XBRL and 4 more
Sources (7)
- NSE capital market bhavcopy, 11 Nov 2026 (CIPLA EQ close)
- Shareholding pattern as of 30 Sep 2026 (NSE XBRL)
- Q2 FY27 consolidated results, Integrated Filing (Financials) XBRL
- Q1 FY27 consolidated results, Integrated Filing (Financials) XBRL
- Q4 FY26 / FY26 consolidated results, Integrated Filing (Financials) XBRL
- Q3 FY26 consolidated results, Integrated Filing (Financials) XBRL
- Integrated Annual Report 2025-26 (FY26)
23How it got here
23How it got here
How did Cipla get here?
1935
Milestone
Incorporated
Cipla was incorporated in 1935, with its registered office in Mumbai.
2001
Business-model change
Low-cost HIV medicines for Africa
Cipla says it offered a triple HIV therapy in Africa at under US$1 a day in 2001.
2016
Business-model change
Bought US generics makers
In FY16 (Apr 2015–Mar 2016) Cipla bought InvaGen and Exelan Pharmaceuticals in the US for US$550 million, funded with debt (CARE).
2023
Crisis
US FDA warning letter for Pithampur
The US FDA classed the Pithampur plant OAI in Aug 2023 and issued a warning letter dated 17 Nov 2023.
2024
Milestone
Promoter-group share sale
Hamied family members and Okasa Pharma sold 2.53% of Cipla on 15 May 2024; the promoter group held 31.67% after.
2025
Milestone
New medicines from partners in India
Launched Eli Lilly's Yurpeak (10 Dec 2025), signed for four Pfizer brands (19 Dec 2025) and bought perpetual rights to Novartis's Galvus brands for ₹1,107 crore.
2026
Crisis
Lanreotide supply stopped
Supply from partner Pharmathen paused in Jan 2026, and Cipla USA recalled unexpired batches in Mar 2026. FY26 North America sales fell 13%.
2026
Milestone
New CEO and US inhaler approvals
Achin Gupta became MD and Global CEO on 1 Apr 2026. The US FDA approved generic Ventolin (23 Apr 2026) and generic Advair Diskus (27 Jul 2026).
Sources (15)
- Business Responsibility and Sustainability Report FY26
- Press release: Q2 FY27 financial results
- CARE Ratings press release: Cipla Limited, bank facilities reaffirmed CARE AAA; Stable / CARE A1+
- USFDA classifies Pithampur inspection as Official Action Indicated (OAI)
- USFDA Warning Letter dated 17 Nov 2023 for Pithampur
- Clarification: promoter group members sold 2.53% of shares on 15 May 2024
- Launch of Yurpeak (tirzepatide) in India under distribution agreement with Eli Lilly
- Exclusive 5-year supply and marketing agreement for four Pfizer brands in India
- Unaudited financial results Q3 FY26 (quarter ended 31 Dec 2025; scanned)
- Update on lanreotide supply after USFDA observations at Pharmathen
- Cipla USA to recall unexpired lanreotide batches
- Press release: Q4 FY26 and FY26 results
- Umang Vohra resigns as director w.e.f. 1 Apr 2026 on completing his term as MD & Global CEO
- USFDA approval for first AB-rated generic of Ventolin HFA (albuterol)
- USFDA approval for generic Advair Diskus
24Sources and changes
Where every number on this page comes from
Sources (68 documents)
- S1Integrated Annual Report 2025-26 (FY26) · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 1 Jun 2026
- S2Integrated Annual Report 2024-25 (FY25) · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 19 Jun 2025
- S3Annual Report 2023-24 (FY24) · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 26 Jul 2024
- S4Annual Report 2022-23 (FY23; NSE zip) · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 18 Jul 2023
- S5Annual Report 2021-22 (FY22; NSE zip) · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 5 Sep 2022
- S6Q2 FY27 consolidated results, Integrated Filing (Financials) XBRL · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 27 Oct 2026
- S7Unaudited financial results Q2 FY27 (quarter and half year ended 30 Sep 2026) · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 27 Oct 2026
- S8Press release: Q2 FY27 financial results · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 27 Oct 2026
- S9Investor presentation Q2 FY27 · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 27 Oct 2026
- S10Q2 FY27 earnings call transcript (call 27 Oct 2026) · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 30 Oct 2026
- S11Q1 FY27 consolidated results, Integrated Filing (Financials) XBRL · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 23 Jul 2026
- S14Q1 FY27 earnings call transcript (call 23 Jul 2026) · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 27 Jul 2026
- S15Q4 FY26 / FY26 consolidated results, Integrated Filing (Financials) XBRL · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 13 May 2026
- S16Press release: Q4 FY26 and FY26 results · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 13 May 2026
- S17Q4 FY26 earnings call transcript (call 13 May 2026) · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 15 May 2026
- S18Q3 FY26 consolidated results, Integrated Filing (Financials) XBRL · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 23 Jan 2026
- S19Unaudited financial results Q3 FY26 (quarter ended 31 Dec 2025; scanned) · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 23 Jan 2026
- S21Q3 FY26 earnings call transcript (call 23 Jan 2026) · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 27 Jan 2026
- S22Q2 FY26 consolidated results, Integrated Filing (Financials) XBRL · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 30 Oct 2025
- S23Press release: Q2 FY26 results · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 30 Oct 2025
- S24Q1 FY26 consolidated results, Integrated Filing (Financials) XBRL · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 25 Jul 2025
- S26Q4 FY25 / FY25 consolidated results, Integrated Filing (Financials) XBRL · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 13 May 2025
- S27Press release: Q4 FY25 and FY25 results · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 13 May 2025
- S28Q4 FY25 earnings call transcript (call 13 May 2025) · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 16 May 2025
- S29Q3 FY25 consolidated results XBRL · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 29 Jan 2025
- S31Press release: Q4 FY24 and FY24 results · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 10 May 2024
- S32Q4 FY24 / FY24 consolidated results XBRL · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 11 May 2024
- S33Q4 FY23 / FY23 consolidated results XBRL · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 12 May 2023
- S34Q4 FY22 / FY22 consolidated results XBRL · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 11 May 2022
- S35Shareholding pattern as of 31 Dec 2023 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 19 Jan 2024
- S36Shareholding pattern as of 31 Mar 2024 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 19 Apr 2024
- S37Shareholding pattern as of 30 Jun 2024 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 20 Jul 2024
- S38Shareholding pattern as of 30 Sep 2024 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Oct 2024
- S39Shareholding pattern as of 31 Dec 2024 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 20 Jan 2025
- S40Shareholding pattern as of 31 Mar 2025 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Apr 2025
- S41Shareholding pattern as of 30 Jun 2025 (re-filed 21 Oct 2025) (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Oct 2025
- S42Shareholding pattern as of 30 Sep 2025 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Oct 2025
- S43Shareholding pattern as of 31 Dec 2025 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Jan 2026
- S44Shareholding pattern as of 31 Mar 2026 (revised filing 11 Aug 2026; original 21 Apr 2026) (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 11 Aug 2026
- S45Shareholding pattern as of 30 Jun 2026 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Jul 2026
- S46Shareholding pattern as of 30 Sep 2026 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Oct 2026
- S47CARE Ratings press release: Cipla Limited, bank facilities reaffirmed CARE AAA; Stable / CARE A1+ · CARE Ratings Limited · Tier 2: rating agency or regulator · 26 Aug 2025
- S48Business Responsibility and Sustainability Report FY26 · Cipla Ltd (filed with NSE) · Tier 1: company or exchange filing · 1 Jun 2026
- S49NSE capital market bhavcopy, 11 Nov 2026 (CIPLA EQ close) · National Stock Exchange of India · Tier 1: company or exchange filing · 11 Nov 2026
- S51USFDA classifies Pithampur inspection as Official Action Indicated (OAI) · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 5 Aug 2023
- S52USFDA Warning Letter dated 17 Nov 2023 for Pithampur · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 18 Nov 2023
- S53USFDA follow-up cGMP inspection at Pithampur, 17-25 Aug 2026: 7 observations in Form 483 · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 25 Aug 2026
- S56USFDA classifies Goa inspection (Jun 2024) as VAI · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 30 Oct 2024
- S58USFDA classifies Patalganga inspection as VAI · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 25 Jun 2024
- S60USFDA classifies Kurkumbh inspection as VAI · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 13 Jul 2024
- S62USFDA classifies Virgonagar inspection as VAI · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 8 Feb 2025
- S68USFDA classifies Bommasandra inspection as VAI · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 5 Aug 2025
- S72USFDA classifies Verna (Goa) Apr 2026 inspection as VAI · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 11 Jun 2026
- S77Clarification: USFDA Form 483 at partner Pharmathen (lanreotide supplier) · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 7 Jan 2026
- S78Update on lanreotide supply after USFDA observations at Pharmathen · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 14 Jan 2026
- S79USFDA classifies Pharmathen (Rodopi, Greece) inspection as OAI · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 21 Feb 2026
- S80Cipla USA to recall unexpired lanreotide batches · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 9 Mar 2026
- S81Umang Vohra resigns as director w.e.f. 1 Apr 2026 on completing his term as MD & Global CEO · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 30 Mar 2026
- S82Board recommends B S R & Co. LLP as statutory auditor from the 90th AGM · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 13 May 2025
- S8390th AGM approves B S R & Co. LLP; Walker Chandiok & Co LLP completes second term · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 25 Jun 2026
- S84Clarification: promoter group members sold 2.53% of shares on 15 May 2024 · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 15 May 2024
- S85Launch of Yurpeak (tirzepatide) in India under distribution agreement with Eli Lilly · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 10 Dec 2025
- S86Exclusive 5-year supply and marketing agreement for four Pfizer brands in India · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 19 Dec 2025
- S87USFDA approval for first AB-rated generic of Ventolin HFA (albuterol) · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 23 Apr 2026
- S88USFDA approval for generic Advair Diskus · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 27 Jul 2026
- S9060:40 biologics joint venture agreement with Kemwell Biopharma · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 2 Mar 2026
- S91Board: up to US$100 mn into Cipla (EU) for InvaGen; P R Ramesh Vice-Chairman · Cipla Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 19 Mar 2026
- S92Sun Pharmaceutical Industries: investor presentation, September 2026 (India formulation market share chart, AIOCD AWACS MAT Jun 2026) · Sun Pharmaceutical Industries Ltd (company IR site) · Tier 1: company or exchange filing · 22 Sep 2026
Changes to this page (v1 · 11 Nov 2026)
- v1 · 11 Nov 2026First version. (first version)
Numbers come only from tier 1 and tier 2 sources. Read how we research.
Disclaimer
For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.
Read the full disclaimerHide the full disclaimer
Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.
All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management are reported as statements, with their date and source; they are not our forecasts.